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Research Article
2-D difference gel electrophoresis of the lung
squamous cell carcinoma versus normal sera
demonstrates consistent alterations in the
levels of ten specific proteins
Most lung cancers are diagnosed too late for curative treatment to be possible, therefore
early detection is crucial. Serum proteins are a rich source of biomarkers and have the
potential to be used as diagnostic and prognostic indicators for lung cancer. In order to
examine differences in serum levels of specific proteins associated with human lung squa-
mous carcinoma, immunodepletion of albumin and five other high-abundant serum pro-
teins followed by 2-D difference gel electrophoresis (DIGE) analysis and subsequent MS
was used to generate a panel of proteins found to be differentially expressed between the
cancer and normal samples. Proteins found to have increased abundance levels in squa-
mous cell carcinoma sera compared to normal sera included apolipoprotein A-IV precursor,
chain F; human complement component C3c, haptoglobin, serum amyloid A protein pre-
cursor and Ras-related protein Rab-7b. Proteins found to have lower abundance levels in
squamous cell carcinoma sera compared to normal sera included alpha-2-HS glycoprotein,
hemopexin precursor, proapolipoprotein, antithrombin III and SP40; 40. The data pre-
sented here demonstrate that high-abundant protein removal combined with 2-D DIGE is a
powerful strategy for the discovery of potential biomarkers. The identification of lung can-
cer-specific biomarkers is crucial to early detection, which in turn could lead to a dramatic
increase in survival rates.
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1 Introduction
Over 1 million people are diagnosed with lung cancer each
year [1]. Most lung cancer is diagnosed too late for curative
treatment to be possible. Efforts at early detection and treat-
ment have had little success to date and hence the overall
prognosis remains poor. In the majority of those diagnosed
with lung cancer, the disease has already metastasised at the
time of diagnosis. Lung cancer comprises broadly of two
groups, small cell lung carcinoma (SCLC) and non-small cell
lung carcinoma (NSCLC). NSCLC comprises more than 80%
of lung cancers including squamous cell carcinoma, adeno-
carcinoma and large cell carcinoma, with squamous carci-
noma being the most common type.
A major factor in the high mortality of lung cancer
patients is the presence of metastatic tumours in approxi-
mately two-thirds of patients at time of diagnosis [2]. Detec-
tion of cancer in these patients at earlier stages would
increase survival rates dramatically. The identification of
lung cancer-specific biomarkers is critical to early detection.
The pathophysiology of lung squamous cell carcinoma
development is complex and incompletely understood.
Genetic alterations involved in the pathogenesis of lung
cancer produce proteins involved in cell growth, invasion/
metastasis, differentiation, cell cycle processes, apoptosis
and angiogenesis. Discovering these mechanisms and path-
ways will undoubtedly lead to new ways in dealing with pre-
vention, early detection and therapy, for example, expression
profiling can subclassify lung adenocarcinoma in terms of
predicting length of survival [3].
A number of potential biomarkers have recently been
identified, but currently, no satisfactory biomarkers are
available to screen for lung cancer due to low specificity and
sensitivity [4, 5]. Lung cancer biomarkers have the potential
to be involved in patient screening, monitoring of cancer
progression, treatment response and as a predictive factor for
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recurrence [6]. No single biomarker with 100% sensitivity
and 100% specificity for lung cancer is likely to be dis-
covered. Employment of panels of biomarkers with different
individual sensitivities and specificities is likely to be more
powerful. Panels of biomarkers from many different sources
including the proteome, peptidome, fragmentome and
degradome will undoubtedly enhance the ability to diagnose
specific cancers at an early stage.
In order to examine differences in serum protein levels
associated with human lung squamous carcinoma (hLSC), a
proteomics-based approach was initiated involving immuno-
depletion of serum samples, 2-D difference gel electrophore-
sis (DIGE) analysis and subsequent MS to generate a panel of
factors found to be differentially expressed between the can-
cerous and noncancerous samples. 2-D DIGE is a powerful
and widely used method for the analysis of complex protein
mixtures and together with powerful fractionation methods,
such as immunodepletion, low-abundant proteins will be
detectable and could prove to be a rich source of biomarkers.
2 Materials and methods
2.1 Serum samples
The patient group studied comprised eight individuals with
NSCLC. All patients were treated at St. Vincent’s University
Hospital (SVUH), Dublin, between 2002 and 2003 and
approval to conduct this study was granted by the SVUH
Ethics Committee. A pooled sample, consisting of equal
amounts of each of the 16 experimental samples, was made
and used as a pooled internal standard. Blood samples
(10 mL) were collected preoperatively in glass tubes without
additive (10 mL BD Vacutainer No Additive, BD) and allowed
to clot at room temperature for 120 min. Serum was sepa-
rated by centrifugation at 1500 rpm for 15 min at room tem-
perature. Aliquots of serum (1 mL) were taken and stored at -
807C until ready for use. The time from collection to frozen
storage was no more than 3 h.
2.2 Removal of high-abundance proteins from serum
samples
Serum samples were processed using a Multiple Affinity
Removal Spin Cartridge (Agilent Technologies), which
selectively removes albumin, IgG, IgA, antitrypsin, trans-
ferrin and haptoglobin from the serum sample. Samples
were processed according to the manufacturer’s instruc-
tions. For each sample, a low-abundance fraction was col-
lected and concentrated using 5000 Da molecular mass cut-
off spin concentrators (Agilent Technologies). Samples were
subsequently cleaned prior to labelling using a 2-D Cleanup
Kit (Bio-Rad). The protein pellets were resuspended in ice-
cold 20 mM Tris, 7 M urea, 2 M thiourea, 4% CHAPS
pH 8.5 buffer. Protein quantification was performed using
the Quick Start Bradford Protein Assay (Bio-Rad) absorb-
ance at 595 nm using BSA as a protein standard. Approxi-
mately 90% of total serum protein is removed by this
method.
2.3 DIGE labelling
Samples were labelled with N-hydroxy succinimidyl ester-
derivatives of the cyanine dyes Cy2, Cy3 and Cy5 following a
standard protocol [7]. Typically, 50 mg of lysate was minimally
labelled with 200 pmol of either Cy3 orCy5 for comparison on
the same 2-D gel. Labelling reactions were performed on ice
in the dark for 30 min and then quenchedwith a 50-foldmolar
excess of free lysine to dye for 10 min on ice. A pool of all
samples was also prepared and labelled with Cy2 to be used as
a standard on all gels to aid image matching and crossgel sta-
tistical analysis. The Cy3 and Cy5 labelling reactions (50 mg of
each) from each lysate were mixed and run on the same gels
with an equal amount (50 mg) of Cy2-labelled standard.
2.4 Protein separation by 2-DE and gel imaging
A 24 cm linear immobilised pH gradient (IPG) strips, pH 4–
7, were rehydrated in rehydration buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 0.5% IPG buffer, 50 mM DTT) over-
night, according to the manufacturer’s guidelines. IEF was
performed using an IPGphor apparatus (GE Healthcare) for
a total of 40 kV/h at 207C, 50 mA. Strips were equilibrated for
20 min in 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% v/v gly-
cerol, 1% w/v SDS containing 65 mM DTT and then for
20 min in the same buffer containing 240 mM iodoaceta-
mide. Equilibrated IPG strips were transferred onto
18 620 cm2 12.5% uniform polyacrylamide gels poured be-
tween low fluorescence glass plates. Strips were overlaid with
0.5% w/v low-melting-point agarose in running buffer con-
taining bromphenol blue. Gels were run using the Ettan Dalt
6 apparatus (GE Healthcare) at 2.5 W/gel for 30 min then
100 W in total at 107C until the dye front had run off the
bottom of the gels. All the images were collected on a
Typhoon 9400 Variable Mode Imager (GE Healthcare). Sta-
tistics and quantitation of protein expression were carried
out in Decyder software (GE Healthcare).
2.5 Spot digestion and MS analysis
Excision of protein spots, trypsin digestion and protein iden-
tification by MS analysis using an Ettan MALDI-TOF Pro
instrument from GE Healthcare was performed according to
an established methodology. Preparative gels containing
300 mg of protein were fixed in 30% v/v methanol, 7.5% v/v
acetic acid overnight and washed in water, and total protein
was detected by poststaining with SyproRuby dye (Molecular
Probes) for 3 h at room temperature or Colloidal Coomassie
(Sigma) for 2 h at room temperature. Excess dye was removed
by appropriate destaining/washing methods. SyproRuby-
stained gels were imaged using a Typhoon 9400 Variable
Mode Imager (GE Healthcare) at the appropriate excitation
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and emission wavelengths for the stain. The subsequent gel
image was imported into the BVA module of DeCyder soft-
ware and was matched to images generated from DIGE anal-
ysis. Spots of interest were selected and confirmed using this
software for subsequent picking using an Ettan Spot Picker.
Gel plugs were placed into a presilconised 1.5 mL plastic tube
for destaining, desalting and washing steps. The remaining
liquid above the gel plugs was removed and sufficient ACN
was added in order to cover the gel plugs. Following shrinkage
of the gel plugs, ACN was removed and the protein-contain-
ing gel pieces were rehydrated for 5 min with a minimal vol-
ume of 100 mMammonium bicarbonate. An equal volume of
ACN was added and after 15 min of incubation the solution
was removed from the gel plugs and the samples then dried
down for 30 min using a vacuum centrifuge. Individual gel
pieces were then rehydrated in digestion buffer (12.5 ng tryp-
sin per mL of 10% ACN 40 mM ammonium bicarbonate) to
cover the gel pieces. More digestion buffer was added if all the
initial volumehad been absorbedby the gel pieces. Exhaustive
digestion was carried out overnight at 377C. After digestion,
the samples were centrifuged at 12 0006g for 10 min using a
bench top centrifuge. The supernatant was carefully removed
from each sample and placed into clean and silconised plastic
tubes. Samples were stored at 2707C until analysed by MS.
For spectrometric analysis, mixtures of tryptic peptides from
individual samples were desalted using Millipore C-18 Zip-
Tips (Millipore) and eluted onto the sample plate with the
matrix solution (5 mg/mL a-cyano-4-hydroxycinnamic acid in
50% ACN/0.1% TFA v/v). Mass spectra were recorded using
the MALDI-TOF instrument operating in the positive reflec-
tor mode at the following parameters: accelerating voltage
20 kV; and pulsed extraction: on (focus mass 2500). Internal
and external calibration was performed using trypsin auto-
lysis peaks at m/z 842.50, m/z 2211.104 and Pep4 mix
respectively. The mass spectra were analysed using MALDI
evaluation software (GE Healthcare), and protein identifica-
tion was achieved with the PMF Pro-Found search engine for
peptide mass fingerprints. Results were also confirmed using
MASCOT, an alternate search engine to identify proteins by
PMF.
Lower-abundant proteins not identified by MALDI-TOF
were digested with tryspin and analysed by 1-D LC-MS using
the Ettan™ MDLC system (GE Healthcare) in high-through-
put configuration directly connected to a Finnigan™ LTQ™
(Thermo Electron). Samples were concentrated and desalted
on RPC trap columns (Zorbax™ 300SB C18, 0.3 mm65 mm,
Agilent Technologies, and the peptides were separated on a
nano-RPCcolumn (Zorbax 300SB C18, 0.075 mm6100 mm,
Agilent Technologies) using a linear ACN gradient from 0 to
65% ACN (Sigma) over 60 min. All buffers used for nano-LC
separation contained 0.1% formic acid (Fluka) as the ion
pairing reagent. Full scan mass spectra were recorded in
profile mode and tandem mass spectra in centroid mode.
The peptides were identified using the information in the
tandem mass spectra by searching against the Swiss-Prot
database using SEQUEST™.
2.6 Statistical analysis
Two-sided, Student’s t-tests were used to analyse differences
in protein levels between squamous cell carcinoma and nor-
mal disease free samples. A p-value of less than 0.05 was
considered statistically significant.
2.7 1-D gel and immunoblot analysis
Protein (8 mg) was loaded onto 12% NuPAGE Bis–Tris gels
(Invitrogen) and electrophoretically separated using a MOS/
SDS buffer. The samples were run according to the manu-
facturer’s instructions and were stained using colloidal Coo-
massie blue (Sigma). Electrophoretic transfer of proteins to
Hybond-ECL NC membranes (GE Healthcare) was carried
out using a Bio-Rad Transblot SD cell (Bio-Rad). Proteins
were transferred for 50 min at 0.34 mA. Efficiency of transfer
was evaluated using Ponceau-S-Red staining of NC mem-
branes, followed by destaining in PBS (50 mM sodium
phosphate, 0.9% w/v NaCl, pH 7.4). Membranes were
blocked for 1 h in 5% w/v fat-free milk powder in PBS con-
taining 0.5% Tween 20. Membranes were then incubated
overnight at 47C with the primary antibody, serum albumin
(ab10241); haptoglobin (ab14248) and actin (ab1801)
(Abcam). NC replicas were subsequently twice washed for
10 min in blocking solution and then incubated with corre-
sponding peroxidase-conjugated secondary antibody for 1 h
at room temperature. NC membranes were washed twice for
10 min in blocking solution and rinsed twice for 10 min in
PBS. Visualisation of immuno-decorated 1-D bands was car-
ried out using an ECL kit (GE Healthcare).
3 Results
3.1 Clinical specimens
Sera from eight male patients with squamous cell lung carci-
noma (Table 1) were analysed in this study. The patients age in
range from 61 to 79 years. The tumour ranges in size from 2.1
to 7 cm. Eight healthy male disease free samples were used in
the control group with an age range of 26–56 years.
3.2 Immunodepletion of high-abundant serum
proteins
The serum proteome constitutes a highly complex array of
circulating proteins, and is a rich source of potential diagnos-
tic and prognostic biomarkers. The immunodepletion tech-
nique involves using multiple affinity removal columns
which contain affinity-purified polyclonal antibodies to
rapidly remove more than 99% of targeted proteins (albumin,
Ig G, Ig A, a-1-antitrypsin, transferrin and haptoglobin) with
minimal nonspecific removal of other proteins. The result of
immunodepletion on a colloidal Coomassie blue-stained 1-D
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Table 1. Clinical information for patients diagnosed with squamous cell carcinoma of the lung
Specimen no. Diagnosis Gender Type Size Grade Smoking Metastasis
1 56 Male Sq cell Ca 5.4 3 Yes None
2 65 Male Sq cell Ca 6.6 3 Yes None
3 64 Male Sq cell Ca 3.7 3 Yes Yes, to peribronchial lymph nodes
4 74 Male Sq cell Ca 2.1 2 Yes None
5 62 Male Sq cell Ca 7 3 Yes Yes, three mediastinal lymph nodes
6 58 Male Sq cell Ca 2.4 2 Yes None
7 60 Male Sq cell Ca 6 2 Yes Yes, to peribronchial lymph nodes
8 76 Male Sq cell Ca 2.5 3 Yes None
Sq cell Ca, Squamous cell Carcinoma.
Figure 1. Colloidal Coomassie blue-stained 1-D gel of raw and immuno-depleted serum showing an increased number of visible proteins
that were previously masked due to the presence of high-abundance proteins. Western blot analysis of raw and immuno-depleted serum
using an antibody to albumin showing the effectiveness of the immuno-depletion column in removing selected high-abundance proteins.
gels where removal of high-abundant proteins like albumin
allow evaluation of lower-abundant proteins previously
masked due to the overpowering presence of the immuno-
depleted proteins (Fig. 1). Recent papers have also confirmed
the marked increase in detectable proteins due to immuno-
depletion [8, 9]. Western blot analysis of raw and immuno-
depleted serum using an antibody to albumin also shows the
effectiveness of the immuno-depletion column (Fig. 1).
3.3 DIGE analysis of the immunodepleted serum
proteome
Fifty micrograms of protein from each sample was labelled
with Cy2, Cy3 or Cy5. Eight individual samples of squamous
cell lung carcinoma serum and eight samples of normal
serum were labelled with Cy3 and Cy5 respectively. All 16
samples employed in the experiment were used in the Cy2
labelled internal pooled standard. Samples were combined
and separated by 2-DE. For DeCyder image analysis, the dif-
ferential in-gel analysis mode of DeCyder was first used to
merge the Cy2, Cy3 and Cy5 images for each gel and to detect
spot boundaries for the calculation of normalised spot
volumes/protein abundance. At this stage, features resulting
from nonprotein sources, namely dust particles and scrat-
ches, were filtered out. The analysis was used to rapidly cal-
culate abundance differences between samples run on the
same gel. The biological variation analysis mode of DeCyder
was then used to match all pairwise image comparisons
from difference in-gel analysis for a comparative crossgel
statistical analysis. Operator intervention was required at this
© 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
4306 P. Dowling et al. Electrophoresis 2007, 28, 4302–4310
point to set landmarks on gels for more accurate crossgel
image superimposition. Comparison of normalised Cy3 and
Cy5 spot volumes with the corresponding Cy2 standard spot
volumes within each gel gave a standardised abundance.
This value was compared across all gels for each matched
spot and a statistical analysis was performed (Fig. 2).
3.4 3-D images, statistics and MS
Examples for the evaluation by DeCyder of alterations in spot
intensities using the DIGE system are displayed in Fig. 3. To
show visually alterations in corresponding spot intensity
proportions, selected spots are displayed as 3-D images. Fig-
ure 4 also displays the associated graph views of standardised
log abundances of the selected spots among analysed gel
replicates. The differentially expressed proteins included in
the table all had a p-value of less than 0.05. Mass spectra were
recorded using the Ettan MALDI-TOF Pro instrument from
GE Healthcare operating in the positive reflector mode at the
following parameters: accelerating voltage 20 kV; and pulsed
extraction: on (focus mass 2500). Internal and external cali-
bration was performed using trypsin autolysis peaks at
m/z 842.50, m/z 2211.104 and Pep4 mix respectively. The
mass spectra were analysed using MALDI evaluation soft-
ware (GE Healthcare), and protein identification was
achieved with the PMF Pro-Found search engine for peptide
mass fingerprints. Lower-abundant proteins not identified by
MALDI-TOF Samples were digested with tryspin and ana-
lysed by 1-D LC-MS using the Ettan™ MDLC system (GE
Healthcare) in high-throughput configuration directly con-
nected to a Finnigan™ LTQ™ (Thermo Electron). Proteins
found to have higher abundance levels in squamous cell car-
cinoma sera compared to normal sera included apolipopro-
tein A-IV precursor (Apo-AIV), chain F; human complement
component C3c, haptoglobin, serum amyloid A protein pre-
cursor and Ras-related protein Rab-7b while proteins found
to have lower abundance levels included AHSG, hemopexin
precursor, proapolipoprotein, antithrombin III (ATH III)
and SP40; 40 (Table 2).
3.5 Western blot analysis
Raw serum from normal and cancer samples were electro-
phoretically separated and transferred to NC before probing
with an antibody to haptoglobin. The results show an
increase in abundance levels of haptoglobin in cancer sam-
ples compared to normal. These results from Western blot
analysis were in good agreement with results from the 2-D
DIGE data (Fig. 5).
4 Discussion
Lung cancer is the leading cause of cancer-related mortality
in both men and women. The prevalence of lung cancer is
second only to that of prostate cancer in men and breast
cancer in women. Early detection of lung cancer would
greatly improve the survival rates. Serum biomarker have
Figure 2. 2-D DIGE image of Cy
2, Cy 3 and Cy 5 labelled squa-
mous cell carcinoma and nor-
mal serum proteins. Protein dif-
ferences were analysed using
2-D PAGE (2-D DIGE) to resolve
proteins based on their pI, in this
case a range of 4–7 was
employed and their molecular
weight to generate a protein
expression map (PEM).
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Figure 3. 3-D image of AHSG. Images were generated using the BVA module of DeCyder software and visually show the abundance levels
for AHSG are lower in the cancer samples compared to normal.
Figure 4. Statistical analysis of AHSG. Statistics were generated using the BVA module of DeCyder software and show an average of 2.43-
fold lower abundance levels for AHSG in the cancer samples compared to normal.
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Tabletpdel 2. Table of proteins found to have higher or lower abundance levels in squamous cell carcinoma sera compared to normal sera
Spot number Protein identification Gene index number Average ratio pI MW (Da) Method of identification
1 AHSG gi)30851645) 22.43 5.4 40 110 MALDI-TOF
2 Apo-AIV gi)114006) 3.04 5.3 45 350 MALDI-TOF
3 Chain F; Human
complement
component C3c
gi)78101274) 1.58 4.8 40 210 MALDI-TOF
4 Haptoglobin gi)1212947) 4.42 6.3 38 950 MALDI-TOF
5 Haptoglobin gi)3337390) 3.9 6.1 38 730 MALDI-TOF
6 Haptoglobin gi)3337390) 3.81 6.1 38 730 MALDI-TOF
7 Haptoglobin gi)3337390) 3.58 6.1 38 730 MALDI-TOF
8 Hemopexin precursor gi)386789) 21.3 6.6 52 270 MALDI-TOF
9 Serum amyloid
A protein precursor
gi)134167) 6.35 6.28 13 532 LC-MS/MS
10 Ras-related protein
Rab-7b
gi)50401122) 7.81 6.31 22 511 LC-MS/MS
11 Proapolipoprotein gi)178775) 21.51 5.4 28 940 MALDI-TOF
12 Proapolipoprotein gi)178775) 21.53 5.4 28 940 MALDI-TOF
13 Antithrombin gi)37682619) 21.51 6.3 53 040 LC-MS/MS
14 ‘SP40; 40’ gi)338305) 21.3 5.7 37000 LC-MS/MS
Listed are the protein identities obtained from MALDI-TOF/LC-MS analysis, gene index number, average ratio, theoretical MW and theo-
retical pI. All proteins listed in the table were found to have a statistically significant p-value of less than 0.05.
great potential to facilitate the early detection and for mon-
itoring of treatments/recurrence in patients with lung cancer
in a noninvasive manner. The analysis of the serum pro-
teome in patients with squamous cell carcinoma of the lung
could identify potential biomarkers and provide a greater
understanding of the pathophysiology.
The concentration of haptoglobin in the sera of patients
with squamous cell carcinoma of the lung was found to be
greater than that of the disease free control group. Hap-
toglobin was elevated beyond the normal capacity of the
immunodepletion column and thus appeared in the flow-
through fraction, with an average ratio of 3.9-fold greater
concentration in the patients with squamous cell carcinoma
of the lung. Due to the haptoglobin levels being greater that
the capacity of the column which might have distorted the
result, Western blot analysis was performed on raw serum
from both the normal and cancer samples. This analysis
confirmed a significant elevation in the abundance level of
haptoglobin in the cancer samples compared to normal
samples.
The full range of biological functions of haptoglobin in
cancer is not well understood at present [10]. Intact hap-
toglobin is a glycoprotein mainly secreted by the liver. Hap-
toglobin combines with free plasma hemoglobin, preventing
iron loss and renal damage. Many papers have shown
increased abundance of haptoglobin in lung cancer patients.
Maciel et al. [11] found that haptoglobin was found in greater
levels in serum from adenocarcinoma lung cancer patients.
Bharti et al. [12] findings suggested that serum levels of
alpha-haptoglobin and HGF may serve as useful serum
tumour biomarkers in SCLC.
Other proteins which we found to be of higher abundance
in squamous cell carcinoma sera compared to normal sera
included Apo-AIV, chain F; human complement component
C3c, serum amyloid A protein precursor and Ras-related pro-
tein Rab-7b. Apolipoprotein is a carrier of lipids and regulates
many cellular functions. The level of serum apolipoprotein
was reported to be differentially expressed in colorectal cancer
and adenocarcinoma lung cancer [11, 13]. Complement com-
ponents are important mediators of inflammation and con-
tribute to the regulation of the immune response. We found
chain F; human complement component C3c to be 1.53-fold
increased in squamous cell carcinoma sera. Two recent
reports have shown that elevated levels of C3a were found in
the ascitic fluids of ovarian cancer patients and in patients
with chronic hepatitis C/HCV-related HCC [14, 15].
The serum amyloid A family comprises a number of dif-
ferentially expressed apolipoproteins including acute-phase
SAA1 and SAA2. The serum level of this apolipoprotein
increases in a wide range of different disease conditions
including reported increased levels in lung cancer [16, 17].
Howard et al. showed that using ELISA, SAA was present at
286 ng/mL in the serum of lung cancer patients versus
34.1 ng/mL in the serum of individuals without cancer.
Benson et al. reported that serum amyloid A in carcinoma of
the lung was significantly elevated.
Rab7, a member of the Ras oncogene family, is a small
Rab GTPase that regulates vesicular traffic from early to late
endosomal stages of the endocytic pathway. Northern blot
analysis shows that Rab7b mRNA is expressed in lung cells
[18]. Rab-7b was found in this study to be substantially ele-
vated (7.81-fold on average) in the cancer serum samples.
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Figure 5. Western blot analysis of
raw serum from normal and cancer
samples using antibodies to actin
(loading control) and haptoglobin.
The results confirm the increase in
abundance levels of haptoglobin in
cancer samples compared to nor-
mal. This is a representative blot for
analysis on all samples performed
in triplicate.
Proteins found with lower abundance levels in squamous
cell carcinoma sera compared to normal sera included AHSG,
hemopexin precursor, proapolipoprotein, ATH III and SP40;
40. Alpha-2-HS glycoprotein (AHSG), is a glycoprotein present
in the serum, is synthesised by hepatocytes and is important in
blocking transforming growth factor-beta1 signal transduction,
which is associated with tumour progression. AHSG has been
observed to be depleted in certain tumours compared with
normal tissue [19, 20]. Kawakami et al. [21] reported that
AHSGwas differentially expressed in the sera of hepatocellular
carcinoma (HCC) patients who had undergone curative radio-
frequency ablation treatment and may be a candidate bio-
marker for the development of diagnostic and therapeutic
tools. Hemopexin is a serum glycoprotein that binds haeme
and transports it to the liver for breakdown and iron recovery
and has been reported to be overexpressed in nipple aspirate
fluid (NAF) from patients with early stage breast cancer [22].
Proapolipoprotein, which is hydrolysed by the signal
peptidase and propeptidase, through which apolipoprotein is
generated, was recently reported to be increased in breast
cancer serum patients using 2-D differential gel electropho-
resis [23, 24].
ATH III is a plasma protein synthesised in the liver. Nor-
mal plasma levels are 115 to 160 mg/L. Reduced serum ATH
III levels together with elevated fibrinogen, vWF, and D-di-
mer were found to be associated with poor survival outcome
in ovarian cancer. The author suggests that fibrinogen, vWF,
ATH III and D-dimer levels be used together as prognostic
markers for disease outcome especially in patients with
advanced ovarian cancer within 36 months of disease [25].
SP-40; 40 (serum protein 40 kDa; 40 kDa) or clusterin is
an 80 kDa disulphide-linked, heterodimeric glycoprotein.
Rodriguez-Pineiro et al. [26] have recently shown that serum
clusterin and some of its isoforms could have a potential
value as colorectal tumour markers and are interesting sub-
jects for biomarker studies. Zhang et al. [27] reported that a
loss of clusterin both in serum and tissue correlates with the
tumorigenesis of esophageal squamous cell carcinoma.
Some of our results are consistent with recently published
material on serum biomarkers in lung cancer. Elevated levels of
haptoglobin and serum amyloid Aprotein have previously been
reported in studieson lung cancer. It is not surprising that some
of the proteins identified in this study have been found to be
potential biomarkers for other cancers and are more likely indi-
cators of local inflammatory reaction that is found in lung can-
cer. However, proteins highlighted in this study like AHSG and
Ras-related protein Rab-7b have the potential to be more specif-
ic. By increasing thenumber of potential biomarkersdiscovered
and developing our understanding their role in the pathophy-
siology of squamous cell carcinoma of the lung, such strategies
have enormous potential in influencing the development of
new treatments and more precise screening for this disease.
This study also highlights the effectiveness of 2-D DIGE in
identifying proteins of differing abundance levels between nor-
mal and cancer specimens. Undoubtedly there are limitations
associated with this proteomics approach. However with the
continually development of immuno-depletion columns and
alternate fraction methods 2-D DIGE will be an important plat-
form in discovering potential biomarkers. Together with com-
plementary proteomics approaches that allow researchers dig
deeper into the serum proteome, the establishment of accurate
panelsof biomarkers for specific diseases is certainly achievable.
Serum is a highly complex bodily fluid that contains
proteins ranging in concentrations over at least nine orders
of magnitude. 2-D DIGE coupled to fractionation of serum
has proved to be successful in the discovery of potentially
useful biomarkers. The chances of discovering a single
marker highly specific and sensitive for a particular cancer
seem unattainable. However, panels of biomarkers from the
proteome in combination with markers from the peptidome,
fragmentome and degradome will undoubtedly enhance the
ability to diagnose specific cancers at an early stage.
This work was supported by the PRTLI Cycle 3, pro-
gramme of the Irish Higher Education Authority.
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